Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 31 studies | 33% ± 15% | |
dendritic cell | 18 studies | 41% ± 21% | |
conventional dendritic cell | 17 studies | 27% ± 13% | |
astrocyte | 17 studies | 36% ± 16% | |
monocyte | 16 studies | 25% ± 9% | |
classical monocyte | 14 studies | 31% ± 12% | |
microglial cell | 12 studies | 30% ± 13% | |
myeloid cell | 12 studies | 33% ± 9% | |
non-classical monocyte | 11 studies | 25% ± 10% | |
oligodendrocyte precursor cell | 9 studies | 34% ± 16% | |
adipocyte | 9 studies | 36% ± 16% | |
oligodendrocyte | 8 studies | 28% ± 11% | |
mononuclear phagocyte | 5 studies | 24% ± 10% | |
CD16-positive, CD56-dim natural killer cell, human | 5 studies | 19% ± 4% | |
Mueller cell | 5 studies | 48% ± 14% | |
GABAergic neuron | 4 studies | 31% ± 11% | |
fibroblast | 4 studies | 20% ± 5% | |
glial cell | 4 studies | 32% ± 7% | |
epithelial cell of proximal tubule | 4 studies | 38% ± 13% | |
natural killer cell | 3 studies | 18% ± 1% | |
retinal ganglion cell | 3 studies | 46% ± 24% | |
abnormal cell | 3 studies | 32% ± 10% | |
amacrine cell | 3 studies | 17% ± 1% | |
tissue-resident macrophage | 3 studies | 27% ± 2% | |
intermediate monocyte | 3 studies | 30% ± 10% | |
glutamatergic neuron | 3 studies | 35% ± 14% | |
Schwann cell | 3 studies | 37% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 5889.02 | 2637 / 2642 | 100% | 105.48 | 703 / 705 |
kidney | 100% | 15993.27 | 89 / 89 | 96% | 59.47 | 862 / 901 |
thymus | 100% | 21718.70 | 653 / 653 | 94% | 35.28 | 571 / 605 |
liver | 89% | 2188.97 | 201 / 226 | 90% | 22.52 | 365 / 406 |
pancreas | 95% | 5068.30 | 311 / 328 | 84% | 15.78 | 149 / 178 |
lung | 98% | 4280.80 | 569 / 578 | 78% | 15.70 | 900 / 1155 |
breast | 97% | 6512.63 | 445 / 459 | 58% | 9.68 | 643 / 1118 |
bladder | 100% | 3217.19 | 21 / 21 | 44% | 7.19 | 222 / 504 |
intestine | 100% | 5324.37 | 963 / 966 | 43% | 5.29 | 224 / 527 |
stomach | 79% | 2159.40 | 285 / 359 | 49% | 6.43 | 141 / 286 |
adrenal gland | 83% | 1909.75 | 213 / 258 | 45% | 5.53 | 103 / 230 |
uterus | 61% | 1057.91 | 103 / 170 | 48% | 8.30 | 221 / 459 |
prostate | 93% | 2645.33 | 228 / 245 | 11% | 1.09 | 56 / 502 |
esophagus | 75% | 2925.43 | 1086 / 1445 | 29% | 3.50 | 53 / 183 |
skin | 40% | 807.19 | 730 / 1809 | 63% | 13.19 | 295 / 472 |
lymph node | 0% | 0 | 0 / 0 | 100% | 60.86 | 29 / 29 |
spleen | 100% | 8545.99 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 8183.85 | 1195 / 1204 | 0% | 0 | 0 / 0 |
heart | 97% | 5297.53 | 835 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 93% | 3183.22 | 1240 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 87% | 2725.68 | 808 / 929 | 0% | 0 | 0 / 0 |
ovary | 33% | 597.17 | 60 / 180 | 44% | 5.17 | 189 / 430 |
muscle | 73% | 1855.07 | 590 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 67% | 11.04 | 30 / 45 |
eye | 0% | 0 | 0 / 0 | 16% | 2.00 | 13 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_0005515 | Molecular function | protein binding |
Gene name | RASSF4 |
Protein name | Ras association domain-containing protein 4 Ras association domain family member 4 |
Synonyms | AD037 |
Description | FUNCTION: Potential tumor suppressor. May act as a KRAS effector protein. May promote apoptosis and cell cycle arrest. . |
Accessions | ENST00000428466.1 Q5T737 Q5T739 Q9H2L5 ENST00000484477.2 ENST00000483709.6 ENST00000427758.5 ENST00000340258.10 [Q9H2L5-1] R4GNA4 V9GYK1 |